PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED)

Clinical trials for PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED) explained in plain language.

Never miss a new study

Get alerted when new PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED) trials appear

Sign up with your email to follow new studies for PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Doubling the dose: a new hope for psoriasis patients losing treatment benefits

Disease control Completed

This study tested whether doubling the dose of the drug TA-650 could help patients with moderate-to-severe psoriasis who initially responded to a standard dose but later saw their symptoms return. The trial involved 51 adults with different forms of psoriasis, including plaque ps…

Matched conditions: PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED)

Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control

Last updated Mar 18, 2026 14:40 UTC

PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED)

Get alerted when new PUSTULAR PSORIASIS (EXCLUDING A LOCALIZED) trials appear

Doubling the dose: a new hope for psoriasis patients losing treatment benefits